Nature Communications (Apr 2024)

CoCas9 is a compact nuclease from the human microbiome for efficient and precise genome editing

  • Eleonora Pedrazzoli,
  • Michele Demozzi,
  • Elisabetta Visentin,
  • Matteo Ciciani,
  • Ilaria Bonuzzi,
  • Laura Pezzè,
  • Lorenzo Lucchetta,
  • Giulia Maule,
  • Simone Amistadi,
  • Federica Esposito,
  • Mariangela Lupo,
  • Annarita Miccio,
  • Alberto Auricchio,
  • Antonio Casini,
  • Nicola Segata,
  • Anna Cereseto

DOI
https://doi.org/10.1038/s41467-024-47800-9
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 12

Abstract

Read online

Abstract The expansion of the CRISPR-Cas toolbox is highly needed to accelerate the development of therapies for genetic diseases. Here, through the interrogation of a massively expanded repository of metagenome-assembled genomes, mostly from human microbiomes, we uncover a large variety (n = 17,173) of type II CRISPR-Cas loci. Among these we identify CoCas9, a strongly active and high-fidelity nuclease with reduced molecular size (1004 amino acids) isolated from an uncultivated Collinsella species. CoCas9 is efficiently co-delivered with its sgRNA through adeno associated viral (AAV) vectors, obtaining efficient in vivo editing in the mouse retina. With this study we uncover a collection of previously uncharacterized Cas9 nucleases, including CoCas9, which enriches the genome editing toolbox.